Company Monitoring Page for Roche

latest headlines for company on cafepharma

Potential False Results with Roche Molecular Systems’ SARS-CoV-2 Assay
FDA Law Blog
Thu, 03/18/21 - 10:47 am
Tags:
Roche Molecular Systems, COVID-19, diagnostics, Roche
Roche launches test to monitor emerging coronavirus variants
Pharmaforum
Tue, 03/16/21 - 11:00 am
Tags:
Roche, diagnostics, COVID-19, COVID-19 variants
Roche drops $1.85B for GenMark's testing tech as pandemic, antibiotic resistance threats loom
Endpoints
Mon, 03/15/21 - 10:50 am
Tags:
Roche, Genentech, M&A, GenMark Diagnostics, diagnostics
GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts
Fierce Pharma
Sat, 03/13/21 - 10:19 pm
Tags:
COVID-19, pandemic, GSK, Novo Nordisk, Roche
In the latest twist to IL-6 roller coaster, Roche's Actemra fails PhIII Covid-19 Veklury combo trial
Endpoints
Thu, 03/11/21 - 10:34 am
Tags:
Roche, Actemra, clinical trials, COVID-19, COVID-19 pneumonia, Veklury
Industry-wide accelerated approval review yields four withdrawals
RAPS.org
Wed, 03/10/21 - 10:53 pm
Tags:
FDA, Bristol-Meyers Squibb, Roche, Merck, AstraZeneca, accelerated approvals
Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod
Fierce Pharma
Mon, 03/8/21 - 11:12 am
Tags:
Roche, Tecentriq, bladder cancer
FDA Approves First Biologic for Rare, Debilitating Lung Disease
BioSpace
Sun, 03/7/21 - 01:35 pm
Tags:
FDA, Roche, Genentech, Actemra, SSc-ILD, biologics
Roche is gearing up to knock down an Irish plant—and it's complicated
Fierce Pharma
Thu, 03/4/21 - 11:28 pm
Tags:
Roche, Ireland, drug manufacturing
Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda
Fierce Pharma
Thu, 03/4/21 - 11:21 pm
Tags:
Pfizer, Lorbrena, non-small cell lung cancer, Novartis, Roche, Takeda
A busy year ahead for Parkinson’s disease
EP Vantage
Wed, 03/3/21 - 10:56 am
Tags:
Parkinson's Disease, drug development, AstraZeneca, Roche, Prothena, MeiraGTx, Annovis Bio, Sanofi, Alkahest, Peptron, SAGE Therapeutics
Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
Fierce Biotech
Thu, 02/25/21 - 10:44 am
Tags:
Merck, Pandion, M&A, immune modulators, Amgen, Eli Lilly, Roche
Medtech’s haves and have-nots
EP Vantage
Wed, 02/24/21 - 10:59 am
Tags:
earnings, devices, Medtech, Medtronic, EXACT Sciences, Thermo Fisher, Abbott Labs, Roche, Qiagen, JNJ, Zimmer Biomet, Smith & Nephew, Boston Scientific
The big Covid-19 trials still to report
EP Vantage
Wed, 02/17/21 - 10:48 am
Tags:
COVID-19, clinical trials, Roche, Actemra, GSK, Synairgen, Algernon, Abivax, Corbus
Genentech Could Regain the Blindness-Related Disease Market with New Treatment
BioSpace
Sat, 02/13/21 - 11:01 pm
Tags:
Roche, Genentech, clinical trials, faricimab, age-related macular degeneration, nAMD
Versant spinout lands $80M to go 'much broader' than the old Roche partnership that birthed it
Endpoints
Thu, 02/11/21 - 10:38 pm
Tags:
Versant Ventures, Pipeline Therapeutics, Roche
Arthritis drug cuts deaths in hospitalized Covid-19 patients, major study shows
Stat
Thu, 02/11/21 - 10:50 am
Tags:
Roche, tocilizumab, COVID-19, clinical trials
Heart disease devices lead latest batch of FDA breakthrough nods
Medtech Dive
Wed, 02/10/21 - 10:19 am
Tags:
devices, FDA, cardiovascular disease, Roche, Puzzle Medical Devices, Alleviant Medical, Pedra Technology, Vascular Perfusion Solutions
Roche refreshingly cautious on Alzheimer's hopeful gantenerumab amid growing hype from rivals
Fierce Biotech
Fri, 02/5/21 - 10:52 am
Tags:
Roche, gantenerumab, Alzheimer's disease
Why ipatasertib is not the Akt Astra wants to follow
EP Vantage
Thu, 02/4/21 - 10:39 am
Tags:
Roche, Genentech, ipataserib, triple negative breast cancer, AstraZeneca, capivasertib

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.